NasdaqGS:BIIB 1 Year Share Price vs Fair Value Explore Biogen's Fair Values from the Community and select yours ...

Biogen beat Q2 estimates with cost control and new launches, but MS declines and pipeline risks cloud growth. Find out why ...

In addition to Scotiabank, Biogen also received a Buy from H.C. Wainwright’s Andrew Fein in a report issued today. However, on the same day, Truist Financial maintained a Hold rating on Biogen (NASDAQ ...

Biogen’s new product launches were a major highlight, generating $252 million in revenue. This marked a 26% increase quarter-over-quarter and a 91% increase year-over-year, effectively offsetting ...

Eli Lilly & Biogen's Alzheimer's drugs may offer minimal impact despite aggressive marketing. Click here to get insights on ...

Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...

Investing.com - Shares of Biogen (NASDAQ:BIIB) rose in premarket U.S. trading on Thursday after the drugmaker posted ...

Biogen raised its annual profit forecast and beat estimates for quarterly results on Thursday, as strong demand for its rare ...

After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, ...

Biogen Inc. raised its full-year financial guidance as growing sales of its Alzheimer’s drug helped the biotech company beat ...

Biogen will invest $2 billion more in its existing manufacturing plants in North Carolina, the drugmaker said on Monday, as ...